Dataset Information


Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer.

ABSTRACT: We investigated the diagnostic and prognostic potential of serum N-glycan profiling for castration-resistant prostate cancer (CRPC). We retrospectively investigated serum N-glycan structural analysis by glycoblotting for 287 patients with benign prostatic hyperplasia (BPH), 289 patients with newly diagnosed prostate cancer (PC), 57 patients with PC treated with androgen-deprivation therapy without disease progression (PC-ADT), and 60 patients with CRPC. N-Glycan profiling was compared between the non-CRPC (BPH, newly diagnosed PC and PC-ADT) and CRPC patients. We obtained the quantitative score for CRPC (CRPC N-glycan score) by discriminant analysis based on the combination of 9 N-glycans that were significantly associated with CRPC. The median CRPC N-glycan score was found to be significantly greater in CRPC patients than in non-CRPC patients. The CRPC N-glycan score could classify CRPC patients with sensitivity, specificity, and area under the curve of 87%, 69%, and 0.88, respectively. The CRPC N-glycan score >1.7 points was significantly associated with poor prognosis in patients with CRPC. The glycoprotein analysis showed that not immunoglobulins but ?-1-acid glycoprotein (AGP) were a potential candidate for the carrier protein of N-glycans. The overexpression of specific N-glycans may be associated with their castration-resistant status and be a potential biomarker for CRPC.

SUBMITTER: Matsumoto T 

PROVIDER: S-EPMC6856113 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5518848 | BioStudies
2009-01-01 | S-EPMC2859723 | BioStudies
1000-01-01 | S-EPMC6314965 | BioStudies
2019-01-01 | S-EPMC6754164 | BioStudies
1000-01-01 | S-EPMC5387168 | BioStudies
2019-01-01 | S-EPMC6599459 | BioStudies
2016-01-01 | S-EPMC4777373 | BioStudies
1000-01-01 | S-EPMC5652757 | BioStudies
2015-01-01 | S-EPMC5522730 | BioStudies
2012-01-01 | S-EPMC3399094 | BioStudies